PARP Inhibitor Biomarkers Market by Product Type, End-Users, and Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
Description
Persistence Market Research has recently released a comprehensive report on the worldwide market for PARP inhibitor biomarkers. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global PARP inhibitor biomarkers market from 2025 to 2032.
Key Insights:
PARP Inhibitor Biomarkers Market Size (2025E): USD 1,035.3 Million
Projected Market Value (2032F): USD 1,833.4 Million
Global Market Growth Rate (CAGR 2025 to 2032): 8.5%
PARP Inhibitor Biomarkers Market – Report Scope:
PARP (Poly ADP-ribose polymerase) inhibitor biomarkers are crucial in identifying patients who are likely to benefit from PARP inhibitor therapies, particularly in oncology applications. These biomarkers include BRCA1/2 mutations, homologous recombination deficiency (HRD), and other DNA damage response (DDR) pathway alterations. The market caters to precision oncology practices by aiding clinicians in tailoring cancer therapies, particularly for ovarian, breast, prostate, and pancreatic cancers. As the demand for personalized medicine rises, the adoption of biomarker-driven treatment approaches is accelerating. Advancements in genomic profiling, next-generation sequencing (NGS), and companion diagnostics are significantly contributing to market growth.
Market Growth Drivers:
The global PARP inhibitor biomarkers market is driven by the rising prevalence of cancer and increasing demand for targeted therapies. As PARP inhibitors gain regulatory approval for treating multiple cancers, there is a growing need for companion diagnostic tests to identify eligible patients based on biomarker status. The increasing awareness of BRCA gene mutations and HRD as predictors of response to PARP inhibitors is boosting biomarker testing volumes. Furthermore, expanding applications of PARP inhibitors in maintenance therapy and combination treatment regimens have fueled investments in biomarker research. Government initiatives to promote precision oncology and growing investments in genomic medicine infrastructure are also propelling market growth.
Market Restraints:
Despite strong growth potential, the PARP inhibitor biomarkers market faces several limitations. High costs associated with biomarker testing and next-generation sequencing technologies pose challenges, especially in low- and middle-income regions. Reimbursement hurdles and regulatory complexities surrounding companion diagnostics can delay market entry for new tests. Additionally, limited awareness among clinicians and patients about biomarker testing for PARP inhibitor eligibility hinders broader adoption. Variability in testing standards and access to specialized laboratories further restrict market expansion in underdeveloped areas.
Market Opportunities:
Significant opportunities exist in the development of novel biomarkers beyond BRCA mutations, which can broaden the scope of PARP inhibitor applications. Collaborations between pharmaceutical companies and diagnostic firms to co-develop companion diagnostics present a promising growth avenue. The integration of artificial intelligence and machine learning in genomic data interpretation is expected to enhance biomarker discovery and clinical decision-making. Furthermore, the increasing penetration of telemedicine and at-home genetic testing platforms provides new channels for biomarker testing and patient outreach. Expansion into emerging markets and the evolution of liquid biopsy techniques also represent untapped potential for growth.
Key Questions Answered in the Report:
What are the primary factors driving the growth of the PARP inhibitor biomarkers market globally?
Which biomarker types and cancer indications are driving the adoption of PARP inhibitor testing?
How are technological innovations influencing the competitive landscape of the PARP inhibitor biomarkers market?
Who are the key players contributing to the market, and what strategies are they using to strengthen their positions?
What are the emerging trends and future prospects in the global PARP inhibitor biomarkers market?
Competitive Intelligence and Business Strategy:
Leading players in the global PARP inhibitor biomarkers market, including Myriad Genetics, Foundation Medicine, Thermo Fisher Scientific, and Illumina, Inc., are investing heavily in innovation, strategic partnerships, and co-development of companion diagnostics. These companies are leveraging their expertise in genomic testing and bioinformatics to develop accurate and efficient biomarker assays. Collaborations with pharmaceutical companies like AstraZeneca, Merck, and GlaxoSmithKline aim to accelerate the development of companion diagnostics aligned with PARP inhibitors. Key strategies include expanding testing portfolios, enhancing NGS capabilities, and strengthening global distribution networks to capture market share in both established and emerging regions.
Key Companies Profiled:
Myriad Genetics, Inc.
Illumina, Inc.
Amoy Diagnostics Co., Ltd.
QIAGEN
Agilent Technologies, Inc.
Quest Diagnostics Incorporated
Foundation Medicine, Inc.
OncoDNA
4baseCare
AstraZeneca
Laboratory Corporation of America® Holdings
Genekor | MEDICAL S.A
Cambridge Bioscience Limited
BPS Bioscience, Inc.
BMG Labtech
R&D Systems, Inc (BioTechne)
BellBrook Labs
Abyntek Biopharma S.L.
Epic Sciences
Reaction Biology
PARP Inhibitor Biomarkers Market Segmentation
By Product:
BRCA 1 & 2 Testing Kits
Homologous Recombination Deficiency (HRD) Testing Kits
Homologous Recombination Repair (HRR) Testing Kits
Others
By Application:
Ovarian Cancer
Breast Cancer
Others
By End User:
Hospitals
Pharmaceutical Companies
Diagnostic Laboratories
Academic and Research Institutions
Others
By Region:
North America
Europe
East Asia
South Asia and Oceania
Latin America
Middle East & Africa
Please Note: It will take 5 business days to complete the report upon order confirmation.
Key Insights:
PARP Inhibitor Biomarkers Market Size (2025E): USD 1,035.3 Million
Projected Market Value (2032F): USD 1,833.4 Million
Global Market Growth Rate (CAGR 2025 to 2032): 8.5%
PARP Inhibitor Biomarkers Market – Report Scope:
PARP (Poly ADP-ribose polymerase) inhibitor biomarkers are crucial in identifying patients who are likely to benefit from PARP inhibitor therapies, particularly in oncology applications. These biomarkers include BRCA1/2 mutations, homologous recombination deficiency (HRD), and other DNA damage response (DDR) pathway alterations. The market caters to precision oncology practices by aiding clinicians in tailoring cancer therapies, particularly for ovarian, breast, prostate, and pancreatic cancers. As the demand for personalized medicine rises, the adoption of biomarker-driven treatment approaches is accelerating. Advancements in genomic profiling, next-generation sequencing (NGS), and companion diagnostics are significantly contributing to market growth.
Market Growth Drivers:
The global PARP inhibitor biomarkers market is driven by the rising prevalence of cancer and increasing demand for targeted therapies. As PARP inhibitors gain regulatory approval for treating multiple cancers, there is a growing need for companion diagnostic tests to identify eligible patients based on biomarker status. The increasing awareness of BRCA gene mutations and HRD as predictors of response to PARP inhibitors is boosting biomarker testing volumes. Furthermore, expanding applications of PARP inhibitors in maintenance therapy and combination treatment regimens have fueled investments in biomarker research. Government initiatives to promote precision oncology and growing investments in genomic medicine infrastructure are also propelling market growth.
Market Restraints:
Despite strong growth potential, the PARP inhibitor biomarkers market faces several limitations. High costs associated with biomarker testing and next-generation sequencing technologies pose challenges, especially in low- and middle-income regions. Reimbursement hurdles and regulatory complexities surrounding companion diagnostics can delay market entry for new tests. Additionally, limited awareness among clinicians and patients about biomarker testing for PARP inhibitor eligibility hinders broader adoption. Variability in testing standards and access to specialized laboratories further restrict market expansion in underdeveloped areas.
Market Opportunities:
Significant opportunities exist in the development of novel biomarkers beyond BRCA mutations, which can broaden the scope of PARP inhibitor applications. Collaborations between pharmaceutical companies and diagnostic firms to co-develop companion diagnostics present a promising growth avenue. The integration of artificial intelligence and machine learning in genomic data interpretation is expected to enhance biomarker discovery and clinical decision-making. Furthermore, the increasing penetration of telemedicine and at-home genetic testing platforms provides new channels for biomarker testing and patient outreach. Expansion into emerging markets and the evolution of liquid biopsy techniques also represent untapped potential for growth.
Key Questions Answered in the Report:
What are the primary factors driving the growth of the PARP inhibitor biomarkers market globally?
Which biomarker types and cancer indications are driving the adoption of PARP inhibitor testing?
How are technological innovations influencing the competitive landscape of the PARP inhibitor biomarkers market?
Who are the key players contributing to the market, and what strategies are they using to strengthen their positions?
What are the emerging trends and future prospects in the global PARP inhibitor biomarkers market?
Competitive Intelligence and Business Strategy:
Leading players in the global PARP inhibitor biomarkers market, including Myriad Genetics, Foundation Medicine, Thermo Fisher Scientific, and Illumina, Inc., are investing heavily in innovation, strategic partnerships, and co-development of companion diagnostics. These companies are leveraging their expertise in genomic testing and bioinformatics to develop accurate and efficient biomarker assays. Collaborations with pharmaceutical companies like AstraZeneca, Merck, and GlaxoSmithKline aim to accelerate the development of companion diagnostics aligned with PARP inhibitors. Key strategies include expanding testing portfolios, enhancing NGS capabilities, and strengthening global distribution networks to capture market share in both established and emerging regions.
Key Companies Profiled:
Myriad Genetics, Inc.
Illumina, Inc.
Amoy Diagnostics Co., Ltd.
QIAGEN
Agilent Technologies, Inc.
Quest Diagnostics Incorporated
Foundation Medicine, Inc.
OncoDNA
4baseCare
AstraZeneca
Laboratory Corporation of America® Holdings
Genekor | MEDICAL S.A
Cambridge Bioscience Limited
BPS Bioscience, Inc.
BMG Labtech
R&D Systems, Inc (BioTechne)
BellBrook Labs
Abyntek Biopharma S.L.
Epic Sciences
Reaction Biology
PARP Inhibitor Biomarkers Market Segmentation
By Product:
BRCA 1 & 2 Testing Kits
Homologous Recombination Deficiency (HRD) Testing Kits
Homologous Recombination Repair (HRR) Testing Kits
Others
By Application:
Ovarian Cancer
Breast Cancer
Others
By End User:
Hospitals
Pharmaceutical Companies
Diagnostic Laboratories
Academic and Research Institutions
Others
By Region:
North America
Europe
East Asia
South Asia and Oceania
Latin America
Middle East & Africa
Please Note: It will take 5 business days to complete the report upon order confirmation.
Table of Contents
180 Pages
- 1. Executive Summary
- 1.1. Global PARP Inhibitor Biomarkers Market Snapshot, 2025 and 2032
- 1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
- 1.3. Key Market Trends
- 1.4. Future Market Projections
- 1.5. Premium Market Insights
- 1.6. Industry Developments and Key Market Events
- 1.7. PMR Analysis and Recommendations
- 2. Market Overview
- 2.1. Market Scope and Definition
- 2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Opportunity
- 2.2.4. Key Trends
- 2.3. Macro-Economic Factors
- 2.3.1. Global Sectorial Outlook
- 2.3.2. Global GDP Growth Outlook
- 2.4. COVID-19 Impact Analysis
- 2.5. Forecast Factors - Relevance and Impact
- 3. Value Added Insights
- 3.1. Product Adoption Analysis
- 3.2. Regulatory Landscape
- 3.3. Porter’s Five Forces Analysis
- 3.4. PESTLE Analysis
- 3.5. Promotional Strategies, By Key Players
- 4. Global PARP Inhibitor Biomarkers Market Outlook
- 4.1. Key Highlights
- 4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
- 4.1.2. Absolute $ Opportunity
- 4.2. Market Size (US$ Mn) Analysis and Forecast
- 4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2023
- 4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2025-2032
- 4.3. Global PARP Inhibitor Biomarkers Market Outlook: Product
- 4.3.1. Introduction / Key Findings
- 4.3.2. Historical Market Size (US$ Mn) Analysis, By Product, 2019-2024
- 4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
- 4.3.3.1. BRCA 1 & 2 Testing Kits
- 4.3.3.2. Homologous Recombination Deficiency (HRD) Testing Kits
- 4.3.3.3. Homologous Recombination Repair (HRR) Testing Kits
- 4.3.3.4. Others
- 4.3.4. Market Attractiveness Analysis: Product
- 4.4. Global PARP Inhibitor Biomarkers Market Outlook: Application
- 4.4.1. Introduction / Key Findings
- 4.4.2. Historical Market Size (US$ Mn), By Application, 2019-2024
- 4.4.3. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
- 4.4.3.1. Ovarian Cancer
- 4.4.3.2. Breast Cancer
- 4.4.3.3. Others
- 4.4.4. Market Attractiveness Analysis: Application
- 4.5. Global PARP Inhibitor Biomarkers Market Outlook: End User
- 4.5.1. Introduction / Key Findings
- 4.5.2. Historical Market Size (US$ Mn), By End User, 2019-2024
- 4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
- 4.5.3.1. Hospitals
- 4.5.3.2. Pharmaceutical Companies
- 4.5.3.3. Diagnostic Laboratories
- 4.5.3.4. Academic and Research Institutions
- 4.5.3.5. Others
- 4.5.4. Market Attractiveness Analysis: End User
- 5. Global PARP Inhibitor Biomarkers Market Outlook: Region
- 5.1. Key Highlights
- 5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2024
- 5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2025-2032
- 5.3.1. North America
- 5.3.2. Europe
- 5.3.3. East Asia
- 5.3.4. South Asia and Oceania
- 5.3.5. Latin America
- 5.3.6. Middle East & Africa
- 5.4. Market Attractiveness Analysis: Region
- 6. North America PARP Inhibitor Biomarkers Market Outlook
- 6.1. Key Highlights
- 6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
- 6.2.1. By Country
- 6.2.2. By Product
- 6.2.3. By Application
- 6.2.4. By End User
- 6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
- 6.3.1. U.S.
- 6.3.2. Canada
- 6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
- 6.4.1. BRCA 1 & 2 Testing Kits
- 6.4.2. Homologous Recombination Deficiency (HRD) Testing Kits
- 6.4.3. Homologous Recombination Repair (HRR) Testing Kits
- 6.4.4. Others
- 6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
- 6.5.1. Ovarian Cancer
- 6.5.2. Breast Cancer
- 6.5.3. Others
- 6.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
- 6.6.1. Hospitals
- 6.6.2. Pharmaceutical Companies
- 6.6.3. Diagnostic Laboratories
- 6.6.4. Academic and Research Institutions
- 6.6.5. Others
- 6.7. Market Attractiveness Analysis
- 7. Europe PARP Inhibitor Biomarkers Market Outlook
- 7.1. Key Highlights
- 7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
- 7.2.1. By Country
- 7.2.2. By Product
- 7.2.3. By Application
- 7.2.4. By End User
- 7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
- 7.3.1. Germany
- 7.3.2. France
- 7.3.3. U.K.
- 7.3.4. Italy
- 7.3.5. Spain
- 7.3.6. Russia
- 7.3.7. Turkey
- 7.3.8. Rest of Europe
- 7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
- 7.4.1. BRCA 1 & 2 Testing Kits
- 7.4.2. Homologous Recombination Deficiency (HRD) Testing Kits
- 7.4.3. Homologous Recombination Repair (HRR) Testing Kits
- 7.4.4. Others
- 7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
- 7.5.1. Ovarian Cancer
- 7.5.2. Breast Cancer
- 7.5.3. Others
- 7.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
- 7.6.1. Hospitals
- 7.6.2. Pharmaceutical Companies
- 7.6.3. Diagnostic Laboratories
- 7.6.4. Academic and Research Institutions
- 7.6.5. Others
- 7.7. Market Attractiveness Analysis
- 8. East Asia PARP Inhibitor Biomarkers Market Outlook
- 8.1. Key Highlights
- 8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
- 8.2.1. By Country
- 8.2.2. By Product
- 8.2.3. By Application
- 8.2.4. By End User
- 8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
- 8.3.1. China
- 8.3.2. Japan
- 8.3.3. South Korea
- 8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
- 8.4.1. BRCA 1 & 2 Testing Kits
- 8.4.2. Homologous Recombination Deficiency (HRD) Testing Kits
- 8.4.3. Homologous Recombination Repair (HRR) Testing Kits
- 8.4.4. Others
- 8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
- 8.5.1. Ovarian Cancer
- 8.5.2. Breast Cancer
- 8.5.3. Others
- 8.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
- 8.6.1. Hospitals
- 8.6.2. Pharmaceutical Companies
- 8.6.3. Diagnostic Laboratories
- 8.6.4. Academic and Research Institutions
- 8.6.5. Others
- 8.7. Market Attractiveness Analysis
- 9. South Asia & Oceania PARP Inhibitor Biomarkers Market Outlook
- 9.1. Key Highlights
- 9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
- 9.2.1. By Country
- 9.2.2. By Product
- 9.2.3. By Application
- 9.2.4. By End User
- 9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
- 9.3.1. India
- 9.3.2. Southeast Asia
- 9.3.3. ANZ
- 9.3.4. Rest of South Asia & Oceania
- 9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
- 9.4.1. BRCA 1 & 2 Testing Kits
- 9.4.2. Homologous Recombination Deficiency (HRD) Testing Kits
- 9.4.3. Homologous Recombination Repair (HRR) Testing Kits
- 9.4.4. Others
- 9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
- 9.5.1. Ovarian Cancer
- 9.5.2. Breast Cancer
- 9.5.3. Others
- 9.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
- 9.6.1. Hospitals
- 9.6.2. Pharmaceutical Companies
- 9.6.3. Diagnostic Laboratories
- 9.6.4. Academic and Research Institutions
- 9.6.5. Others
- 9.7. Market Attractiveness Analysis
- 10. Latin America PARP Inhibitor Biomarkers Market Outlook
- 10.1. Key Highlights
- 10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
- 10.2.1. By Country
- 10.2.2. By Product
- 10.2.3. By Application
- 10.2.4. By End User
- 10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
- 10.3.1. Brazil
- 10.3.2. Mexico
- 10.3.3. Rest of Latin America
- 10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
- 10.4.1. BRCA 1 & 2 Testing Kits
- 10.4.2. Homologous Recombination Deficiency (HRD) Testing Kits
- 10.4.3. Homologous Recombination Repair (HRR) Testing Kits
- 10.4.4. Others
- 10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
- 10.5.1. Ovarian Cancer
- 10.5.2. Breast Cancer
- 10.5.3. Others
- 10.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
- 10.6.1. Hospitals
- 10.6.2. Pharmaceutical Companies
- 10.6.3. Diagnostic Laboratories
- 10.6.4. Academic and Research Institutions
- 10.6.5. Others
- 10.7. Market Attractiveness Analysis
- 11. Middle East & Africa PARP Inhibitor Biomarkers Market Outlook
- 11.1. Key Highlights
- 11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
- 11.2.1. By Country
- 11.2.2. By Product
- 11.2.3. By Application
- 11.2.4. By End User
- 11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
- 11.3.1. GCC Countries
- 11.3.2. Egypt
- 11.3.3. South Africa
- 11.3.4. Northern Africa
- 11.3.5. Rest of Middle East & Africa
- 11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
- 11.4.1. BRCA 1 & 2 Testing Kits
- 11.4.2. Homologous Recombination Deficiency (HRD) Testing Kits
- 11.4.3. Homologous Recombination Repair (HRR) Testing Kits
- 11.4.4. Others
- 11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
- 11.5.1. Ovarian Cancer
- 11.5.2. Breast Cancer
- 11.5.3. Others
- 11.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
- 11.6.1. Hospitals
- 11.6.2. Pharmaceutical Companies
- 11.6.3. Diagnostic Laboratories
- 11.6.4. Academic and Research Institutions
- 11.6.5. Others
- 11.7. Market Attractiveness Analysis
- 12. Competition Landscape
- 12.1. Market Share Analysis, 2024
- 12.2. Market Structure
- 12.2.1. Competition Intensity Mapping By Market
- 12.2.2. Competition Dashboard
- 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
- 12.3.1. Myriad Genetics, Inc.
- 12.3.1.1. Overview
- 12.3.1.2. Segments and Products
- 12.3.1.3. Key Financials
- 12.3.1.4. Market Developments
- 12.3.1.5. Market Strategy
- 12.3.2. Illumina, Inc.
- 12.3.3. Amoy Diagnostics Co., Ltd.
- 12.3.4. QIAGEN
- 12.3.5. Agilent Technologies, Inc.
- 12.3.6. Quest Diagnostics Incorporated
- 12.3.7. Foundation Medicine, Inc.
- 12.3.8. OncoDNA
- 12.3.9. 4baseCare
- 12.3.10. AstraZeneca
- 12.3.11. Laboratory Corporation of America® Holdings
- 12.3.12. Genekor | MEDICAL S.A
- 12.3.13. Cambridge Bioscience Limited
- 12.3.14. BPS Bioscience, Inc.
- 12.3.15. BMG Labtech
- 12.3.16. R&D Systems, Inc (BioTechne)
- 12.3.17. BellBrook Labs
- 12.3.18. Abyntek Biopharma S.L.
- 12.3.19. Epic Sciences
- 12.3.20. Reaction Biology
- 13. Appendix
- 13.1. Research Methodology
- 13.2. Research Assumptions
- 13.3. Acronyms and Abbreviations
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.